Clinical Trial Update: A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial for AK105 (anti-PD-1) in metastatic squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)

Snippet

Sponsor: Akeso | Conditions: Lung Cancer Non-small Cell Stage IV, Squamous Cell Lung Cancer | Phase 3 | Status: COMPLETED